News - Oncology, Biotechnology

Filter

Current filters:

OncologyBiotechnology

Popular Filters

1 to 25 of 541 results

Puma Biotech rockets on new neratinib data; amends deal with Pfizer

Puma Biotech rockets on new neratinib data; amends deal with Pfizer

23-07-2014

US development-stage company Puma Biotechnology saw its share more than triple to $190 in after-hours…

BiotechnologyLicensingneratinibOncologyPB272PfizerPuma BiotechResearchTrastuzumabUSA

Zeltia diversifying its business pharma model to finance R&D pipeline

22-07-2014

PharmaMar, biopharmaceutical company which represents the main affiliate of Spanish Grupo Zeltia is diversifying…

AplidinBiotechnologyChugai PharmaceuticalGP PharmLicensingOncologyPharmaMarPM 1183PolitrateResearchZeltia

AstraZeneca's MedImmune announces cancer immunotherapies partnership with Advaxis

AstraZeneca's MedImmune announces cancer immunotherapies partnership with Advaxis

22-07-2014

Anglo-Swedish drug major AstraZeneca says that its global biologics research and development arm MedImmune…

AdvaxisADXS-HPVAstraZenecaBiotechnologyMedImmuneOncologyPapillomavirusResearchSweden

Regeneus's human cancer vaccine pipeline adds almost $4 million to valuation

Regeneus's human cancer vaccine pipeline adds almost $4 million to valuation

22-07-2014

Australian biotech company Regeneus has expanded its portfolio to include licensing of global rights…

AustraliaBiotechnologyFinancialOncologyOsteosarcomaRegeneusResearchSarcoma

PharmaMar and Chugai link up to commercialize Aplidin in Europe

17-07-2014

Spanish drugmaker Zeltia, through its biotech subsidiary PharmaMar, and Japan’s Chugai Pharmaceutical…

AplidinBiotechnologyChugai PharmaceuticalEuropeLicensingOncologyPharmaMarplitidepsinZeltia

Immunocore and Eli Lilly sign $25 million collaboration

Immunocore and Eli Lilly sign $25 million collaboration

16-07-2014

UK-based biotech firm Immunocore and US drug major Eli Lilly today announced they have entered into a…

BiotechnologyEli LillyImmunocoreImmunologyLicensingLillyOncologyUKUSA

Final funding boost for immatics to complete Phase III study

Final funding boost for immatics to complete Phase III study

16-07-2014

Germany’s privately-held immatics biotechnologies GmbH has received 22 million euros ($29 million)…

BiotechnologyFinancialGermanyimmatics biotechnologiesOncologyRenal cell carcinomaResearchSutent

Executive Q&A: Nicholas Saccomano, CSO of Array BioPharma

Executive Q&A: Nicholas Saccomano, CSO of Array BioPharma

15-07-2014

In an interview with The Pharma Letter, Nicholas Saccomano, chief science officer of Array BioPharma,…

Array BioPharmaBiogen IdecBiotechnologyChief science officerHealth Medical PharmaInterviewsMelanomaOncologyProtein kinase inhibitorUSA

Hemispherx links with SA biotech Bioclones on cancer vaccine

Hemispherx links with SA biotech Bioclones on cancer vaccine

14-07-2014

USA-based Hemispherx Biopharma has entered a strategic alliance to develop multiple projects with Bioclones,…

AlferonAmpligenBioclonesBiotechnologyHemispherx BioPharmaOncologyResearchSouth AfricaVaccines

Celgene’s Imnovid now reimbursed in Sweden, Spain and Switzerland

Celgene’s Imnovid now reimbursed in Sweden, Spain and Switzerland

11-07-2014

US biotech firm Celgene’s Imnovid (pomalidomide), called Pomalyst in the USA, is now approved for reimbursement…

BiotechnologyCelgeneFinancialHealthcareImnovidOncologyPomalystSpainSweden

$25 million milestone for Incyte on Japanese approval of Jakavi

$25 million milestone for Incyte on Japanese approval of Jakavi

08-07-2014

US biopharma company Incyte says it has earned a $25 million milestone payment from Swiss drug major…

BiotechnologyBusiness FinanceBusiness FinanceFinancialIncyteJakaviJapanMajorMedicineNovartisOncologyRegulationRuxolitinib

SMC guidance on AstraZeneca’s diabetes drug and Roche’s MabThera

SMC guidance on AstraZeneca’s diabetes drug and Roche’s MabThera

08-07-2014

The Scottish Medicines Consortium (SMC) has issued guidance on Anglo-Swedish drug major AstraZeneca’s…

AstraZenecaBiotechnologydapagliflozinDiabetesMabTheraOncologyRocheUK

BIND Thera and Amgen end their Accurin collaboration

BIND Thera and Amgen end their Accurin collaboration

03-07-2014

US clinical stage drug developer BIND Therapeutics saw its shares plunge 15.8% to $10.84 in after-hours…

AccurinsAmgenBIND TherapeuticsBiotechnologyLicensingOncology

Roche to acquire Seragon in deal that could reach over $1.7 billion

Roche to acquire Seragon in deal that could reach over $1.7 billion

02-07-2014

Swiss drug major Roche says its USA-based biotech subsidiary Genentech has entered into a definitive…

BiotechnologyGenentechMergers & AcquisitionsOncologyRocheSeragon Pharmaceuticals

Breakthrough status for Amgen’s blinatumomab in ALL

01-07-2014

USA-based Amgen, the world's largest independent biotech firm, says that the US Food and Drug Administration…

AmgenBiotechnologyblinatumomabOncologyRegulationUSA

BioAlliance and Topotarget progress merger plan

BioAlliance and Topotarget progress merger plan

01-07-2014

France-base BioAlliance Pharma and Denmark’s Topotarget say that the shareholders of both companies…

BioAlliance PharmaBiotechnologyMergers & AcquisitionsOncologyOnxeoTopotarget

Erbitux equal to Avastin in colorectal cancer survival, FIRE-3 study shows

Erbitux equal to Avastin in colorectal cancer survival, FIRE-3 study shows

30-06-2014

Merck Serono, the biotech subsidiary of Germany’s Merck KGaA, has released positive new clinical trial…

AvastinBiotechnologyErbituxMerck KGaAMerck SeronoOncologyResearchRoche

Affymax decides to wind up company following demise of Omontys

Affymax decides to wind up company following demise of Omontys

25-06-2014

USA-based biotech firm Affymax says that its board of directors has approved the liquidation and dissolution…

AffymaxBiotechnologyFinancialManagementOmontysOncologyTakeda Pharmaceutical

Mersana and Merck KGaA to develop next-gen antibody-drug conjugates

Mersana and Merck KGaA to develop next-gen antibody-drug conjugates

24-06-2014

Privately-held US biotech company Mersana Therapeutics and EMD Serono, the North America biopharmaceutical…

BiotechnologyEMD SeronoMerck KGaAOncologyResearch

Physicians views on EGFR wild-type/untested NSCLC treatment

Physicians views on EGFR wild-type/untested NSCLC treatment

20-06-2014

According to surveyed US and European oncologists, improvement in efficacy endpoints are the most influential…

AstraZenecaBiotechnologyBristol-Myers SquibbEuropeHealthcareMarkets & MarketingMerck & ConivolumabOncologyOno PharmaceuticalpembrolizumabselumetinibUSA

US orphan status for Mirati’s mocetinostat and Alexion’s Soliris

US orphan status for Mirati’s mocetinostat and Alexion’s Soliris

17-06-2014

USA-based Mirati Therapeutics has been granted Orphan Drug designation by the US Food and Drug Administration…

BiotechnologyOncologyRare diseasesRegulation

Celgene exercises option for Agios Pharma’s AG-221

Celgene exercises option for Agios Pharma’s AG-221

17-06-2014

Metabolism specialist Agios Pharmaceuticals says that its partner, biotech major Celgene Corp, has exercised…

AG-221Agios PharmaceuticalsBiotechnologyCelgeneLicensingOncologyRegulationResearchUSA

1 to 25 of 541 results

Back to top